At the end of the run-in phase , 889 patients who did not have progressive disease were entered into the main study , and were randomly allocated using a 1:1 adaptive randomisation method through a third-party interactive voice response system to receive erlotinib ( 150 mg/day ; n = 438 ) or placebo ( n = 451 ) until progression or unacceptable toxicity .
